Skip to main content

Table 1 Clinicopathological characteristics of patients with lung metastases upon initial metastatic breast cancer diagnosis according to breast cancer subtype

From: Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population

Characteristic

HR+/HER2-, N (%)

HR−/HER2+, N (%)

HR+/HER2+, N (%)

Triple-negative, N (%)

p value

All patients

386 (47.7)

116 (14.3)

130 (16.1)

177 (21.9)

 

Age

    

0.015

  < 50

172 (44.6)

44 (37.9)

62 (47.7)

99 (55.9)

 

  ≥ 50

214 (55.4)

72 (62.1)

68 (52.3)

78 (44.1)

 

ECOG

    

0.194

 0

91 (23.6)

24 (20.7)

23 (17.7)

46 (26.0)

 

 1

278 (72.0)

88 (75.9)

102 (78.5)

117 (66.1)

 

 2

17 (4.4)

4 (3.4)

5 (3.8)

14 (7.9)

 

Pathological type

    

0.552

 IDC

355 (92.0)

111 (95.7)

125 (96.2)

168 (94.9)

 

 ILC

9 (2.3)

1 (0.9)

2 (1.5)

3 (1.7)

 

 Others

22 (5.7)

4 (3.4)

3 (2.3)

6 (3.4)

 

T-stage

    

0.065

 T1

104 (26.9)

24 (20.7)

32 (24.6)

47 (26.6)

 

 T2

169 (43.8)

50 (43.1)

52 (40.0)

83 (46.9)

 

 T3

20 (5.2)

6 (5.2)

5 (3.8)

17 (9.6)

 

 T4

18 (4.7)

12 (10.3)

9 (6.9)

6 (3.4)

 

 Unknown

75 (19.4)

24 (20.7)

32 (24.6)

24 (13.6)

 

N-stage

    

0.005

 N0

113 (29.3)

25 (21.6)

30 (23.1)

65 (36.7)

 

 N1

96 (24.9)

23 (19.8)

43 (33.1)

45 (25.4)

 

 N2

66 (17.1)

22 (19.0)

23 (17.7)

31 (17.5)

 

 N3

67 (17.4)

35 (30.2)

20 (15.4)

19 (10.7)

 

 Unknown

44 (11.4)

11 (9.5)

14 (10.8)

17 (9.6)

 

M-stage

    

0.002

 M0

339 (87.8)

88 (75.9)

103 (79.2)

157 (88.7)

 

 M1

47 (12.2)

28 (24.1)

27 (20.8)

20 (11.3)

 

Liver metastases

    

0.001

 No

308 (79.8)

85 (73.3)

88 (67.7)

152 (85.9)

 

 Yes

78 (20.2)

31 (26.7)

42 (32.3)

25 (14.1)

 

Brain metastases

    

0.625

 No

370 (95.9)

108 (93.1)

124 (95.4)

170 (96.0)

 

 Yes

16 (4.1)

8 (6.9)

6 (4.6)

7 (4.0)

 

Bone metastases

    

< 0.001

 No

226 (58.5)

91 (78.4)

89 (68.5)

134 (75.7)

 

 Yes

160 (41.5)

25 (21.6)

41 (31.5)

43 (24.3)

 

Number of metastatic sites

    

0.001

 1

104 (26.9)

28 (24.1)

42 (32.3)

53 (29.9)

 

 2

108 (28.0)

48 (41.4)

37 (28.5)

74 (41.8)

 

  ≥ 3

174 (45.1)

40 (34.5)

51 (39.2)

50 (28.2)

 

Anti-HER2 therapy during first line

    

0.429

 Yes

–

54 (46.6)

54 (41.5)

  

 No

–

62 (53.4)

76 (58.5)

  

DFS

    

< 0.001

  ≤ 2 years

83 (21.5)

47 (40.5)

36 (27.7)

94 (53.1)

 

  > 2 years

256 (66.3)

41 (35.3)

67 (51.5)

63 (35.6)

 

 M1

47 (12.2)

28 (24.2)

27 (20.8)

20 (11.3)

 
  1. HR hormone receptor, HER2 human epidermal growth factor receptor 2, ECOG Eastern Cooperative Oncology Group, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DFS disease-free survival